Dr. Jonathan Levenson is a Senior Advisor for Translational Biology at Ilios Therapeutics. He is also the CSO at FireCyte Therapeutics. Previously, he served as Vice President of Translational Biology at Tiaki Therapeutics, where he was involved in the development of a neuroinflammatory translational platform. Additionally, at Proclara Biosciences, Dr. Levenson oversaw preclinical and nonclinical research and development, focusing on therapeutics for Alzheimer’s disease and systemic amyloidosis. His experience also includes a role as a Senior Scientist at Galenea, and academic appointments at the University of Wisconsin-Madison and Baylor College of Medicine.

Dr. Levenson earned his Ph.D. in Biology from the University of Houston and completed postdoctoral training in the Department of Neuroscience at Baylor College of Medicine. He has contributed to the scientific community through authorship or co-authorship of over 70 research publications, primarily focusing on neuropharmacology and the development of tools for the study and treatment of neuropsychiatric and neurodegenerative diseases. His work encompasses both industry and academia, reflecting a commitment to advancing knowledge and applications in the field of translational biology.